Nordic biotech company raises capital for international obesity study

Pila Pharma was founded in 2014 by former Novo Nordisk researcher Dorte X. Gram (Image: Pila Pharma)

Nordic biotech company, Pila Pharma, has raised SEK10m (£7.28m) in a directed share issue to undertake an international study on a new obesity drug. 

According to Pila Pharma, the study will assess the performance of a particular molecule – a TRPV1-antagonist – in weight loss medications. Specifically, the study will assess the safety of the molecule in increased dosages, as well as expand on the number of study participants to determine whether the molecule has potential as part of a new tablet-based obesity treatment.

An intense battle is being fought for global market shares in the world of weight-reducing medicine. Major players in the market include the likes of Novo Nordisk – which produces Ozempic and Wegovy – and Eli Lilly. With the study, Pila Pharma is aspiring to increase its foothold on the burgeoning market. 

Pila Pharma was founded in 2014 by former Novo Nordisk researcher Dorte X. Gram, who now chairs the company.  She has been accredited as one of the scientists who identified and highlighted the molecule that would later become Semaglutide, which today is the pillar of Ozempic and Wegovy.

 

“With this new capital we aim to explore whether we can lower body weight and thereby play a role in the market and potentially position ourselves uniquely by being the only company working with this particular mechanism for the treatment of obesity and other metabolic diseases” – Gustav H. Gram

Gustav H. Gram,  Pila Pharma CEO, said: “The industry has traditionally focused on Type-2 diabetes, which is also a major market, but in recent years a new market for weight-reducing drugs has emerged. 

“The new molecules, primarily of the type GLP-1, are highly potent, enabling them for potentially quick and significant weight loss in individuals with certain types of obesity. 

“We will now initiate a study aimed at developing a new type of drug with a different mechanism. We’re still at an early stage when it comes to the concepts surrounding weight loss medication, but with demand being as huge as it is, there will be room for many types of products. 

“With this new capital, we aim to explore whether we can lower body weight and thereby play a role in the market and potentially position ourselves uniquely by being the only company working with this particular mechanism for the treatment of obesity and other metabolic diseases.”

Pila Pharma is in phase 2 of the development of its medicine, which can potentially aid in weight loss for obese type-2 diabetics. The company hopes to see the results of the study in about a year from when the study commences, and if successful, they will most likely look to continue with a larger phase 2b study.

“If our study shows an effect on obesity, we will be the first and only company to have successfully used this type of molecule – a TRPV1-antagonist – for the treatment of metabolic diseases,” Gram adds. 

“Until now, this drug class has mostly been recognised in association with pain management. If the results are positive, we will be in a unique position to develop what we in the industry call a “first-in-class”-product.”

Recommended Posts